Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of <i>De Novo</i> Designs of Solid-Binding Peptides.

ACS central science·2026
Same author

Adaptive cargo deletion as an evolutionary dead-end during phage-based directed evolution.

BMC research notes·2026
Same author

Unraveling the Antiviral Efficacy of Surfactants: Deactivation of Nonenveloped Viruses through Synergistic Electrostatic Mechanisms.

ACS nano·2026
Same author

Discovering Plastic-Binding Peptides with Favorable Affinity, Water Solubility, and Binding Specificity Through Deep Learning and Biophysical Modeling.

bioRxiv : the preprint server for biology·2026
Same author

IL-17RA signaling promotes the dedifferentiation of Paneth progenitors through ADAM17 to regenerate gut epithelium post-irradiation.

Nature communications·2026
Same author

In silico peptide self-assembly reveals the importance of N-terminal motifs and the inhibition mechanism of the mutation L38M in α-synuclein fibrillation.

Protein science : a publication of the Protein Society·2026

Related Experiment Video

Updated: Jan 11, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.4K

Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile

Carly M Catella1, Sudeep Sarma1, Caroline M Hinesley2

  • 1Department of Chemical Engineering, North Carolina State University, Raleigh, North Carolina, USA.

Biotechnology and Bioengineering
|November 15, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed peptide inhibitors targeting Clostridioides difficile toxin B (TcdB). These inhibitors show broad efficacy against common TcdB strains, offering a new therapeutic strategy for C. difficile infections.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD
13:34

Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD

Published on: December 30, 2016

11.9K

Related Experiment Videos

Last Updated: Jan 11, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.4K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.3K
Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD
13:34

Production, Crystallization and Structure Determination of C. difficile PPEP-1 via Microseeding and Zinc-SAD

Published on: December 30, 2016

11.9K

Area of Science:

  • Microbiology
  • Toxicology
  • Drug Discovery

Background:

  • Clostridioides difficile infection (CDI) is a growing concern due to hypervirulent and antibiotic-resistant strains.
  • Toxins A (TcdA) and B (TcdB) are key virulence factors causing CDI symptoms like colitis and diarrhea.
  • Targeting toxins offers a therapeutic strategy to complement antibiotics and mitigate resistance.

Purpose of the Study:

  • To rationally discover and optimize potent peptide inhibitors against TcdB.
  • To evaluate the efficacy of these inhibitors against TcdB glucosyltransferase activity and its downstream effects.

Main Methods:

  • Rational design and optimization of peptide sequences.
  • Enzymatic assays to determine inhibition of TcdB glucosyltransferase activity and Michaelis constants (KM) for substrates.
  • In vitro testing using a human colon epithelial cell model to assess barrier integrity and apoptosis.

Main Results:

  • Identified lead peptide sequences that effectively inhibit TcdB glucosyltransferase activity.
  • Demonstrated broad efficacy of selected peptides against the three most prevalent TcdB subtypes.
  • Showed that peptides delayed TcdB-induced loss of epithelial barrier integrity and reduced apoptosis in a human colon cell model.

Conclusions:

  • Novel peptide inhibitors targeting TcdB have been successfully developed.
  • These peptides represent a promising therapeutic approach for managing C. difficile infections.
  • This strategy may enhance current treatments and reduce the development of antibiotic resistance.